Impact on life expectancy of HIV-1 positive individuals of CD4R cell count and viral load response to antiretroviral therapy

AIDS

Volumn 28, Issue 8, 2014, Pages 1193-1202

  May, Margaret T ^a   Gompels, Mark ^b,v   Delpech, Valerie ^c   Porter, Kholoud ^d   Orkin, Chloe ^e   Kegg, Stephen ^f   Hay, Phillip ^g,h   Johnson, Margaret ^h,w   Palfreeman, Adrian ⁱ   Gilson, Richard ^j   Chadwick, David ^c,k   Martin, Fabiola ^l   Hill, Teresa ^m   Walsh, John ⁿ   Post, Frank ^o   Fisher, Martin ^e,p,s   Ainsworth, Jonathan ^q   Jose, Sophie ^m   Leen, Clifford ^o,r,x   Nelson, Mark ^j,s   Anderson, Jane ^t,u   Sabin, Caroline ^m   Babiker, Abdel ^z   Dunn, Daviad ^k   Gazzard, Brian ^j   Phillips, Andrew ^m   Pillay, Deenan ^z   Sachikonye, Memory ^y   Schwenk, Achim ^z   Winston, Alan ⁿ   Mackie, Nicky ⁿ   Huntington, Susie ^z   Thornton, Alicia ^m   Glabay, Adam ^d   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NORTH BRISTOL NHS TRUST   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e BARTS HEALTH NHS TRUST   (United Kingdom)

^f START Team   (United Kingdom)

^g ST GEORGE S HOSPITAL   (United Kingdom)

^h ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^j ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^k SOUTH TEES HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^l York Teaching Hospitals NHS Trust   (United Kingdom)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^o KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^p UK   (United Kingdom)

^q NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

^r NHS LOTHIAN   (United Kingdom)

^s CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^t HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^u MRC CLINICAL TRIALS UNIT   (United Kingdom)

^v ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^w SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^x YORK TEACHING HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^y UK COMMUNITY ADVISORY BOARD   (United Kingdom)

^z Chelsea and Westminster Hospital NHS Foundation Trust ^*

more..

Author keywords

Antiretroviral therapy; Cd4^{+< sup> cell count; HIV; HIV 1 RNA; Life expectancy; Viral load}

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ASIAN; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; ETHNICITY; FOLLOW UP; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIFE EXPECTANCY; LIFE TABLE; MORTALITY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UNITED KINGDOM; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; AGED; EPIDEMIOLOGY; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84922515339     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000243     Document Type: Review

References (41)

1. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011; 343:d6016.
2. Hogg R, Lima V, Sterne JAC, Grabar S, Battegay M, Bonarek M, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies 1. Lancet 2008; 372:293-299.
3. Lewden C, Bouteloup V, De-Wit S, Sabin C, Mocroft A, Wasmuth JC, et al. All-cause mortality in treated HIV-infected adults with CD4>/U500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41:433-445.
4. Zwahlen M, Harris RJ, Hogg R, Costagliola D, May M, de-Wolf F, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in eight industrialized countries. Int J Epidemiol 2009; 38:1624-1633.
5. O'Connor J, Smith C, Lampe F, Johnson M, Sabin C, Phillips A. Failure to achieve an adequate CD4 count response despite regular engagement in HIV care and consistent viral suppression. 19th Annual Conference of the British HIV Association (BHIVA); 16-19 April 2013; Manchester, UK. pp. 12-77.
6. Bofill M, Janossy G, Lee CA, MacDonald-Burns D, Phillips AN, Sabin C, et al. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol 1992; 88:243-252.
7. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies. Lancet 2003; 362:679-686.
8. Marconi VC, Grandits G, Okulicz JF, Wortmann G, Ganesan A, Crum-Cianflone N, et al. Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS. PLoS One 2011; 6:e17956.
9. Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27:973-979.
10. UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-124.
11. Hill T, Hartney T, Chadborn T, Delpech V, Sabin C. Improving the quality of death data in the UK CHIC Study. 15th Annual Conference of the British HIV Association (BHIVA); 1-3 April 2009; Liverpool, UK. pp. 109.
12. Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, et al. Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol 2006; 59:829-835.
13. Delpech V, Brown A, Conti S, Polavarapu V, Yin Z. Reducing onward transmission: viral suppression among key population groups living with HIV in the United Kingdom. 19th Annual Conference of the British HIV Association (BHIVA); 16-19 April 2013; Manchester, UK.
14. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
15. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185-1197.
16. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008; 13:959-967.
17. Justice AC, McGinnis KA, Skanderson M, Chang CC, Gibert CL, Goetz MB, et al. Towards a combined prognostic index for survival in HIV infection: The role of 'non-HIV' biomarkers. HIV Med 2010; 11:143-151.
18. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren J, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26:335-343.
19. Nachega JB, Mugavero MJ, Zeier M, Vitoria M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence 2011; 5:357-367.
20. Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: A meta-analysis. PLoS One 2011; 6:e22003.
21. UK Government. Health and Social Care Act 2012. http://www.legislation.gov.uk/ukpga/2012/7/contents/enacted [Accessed 17 December 2013].
22. Gill MJ, May MT, Lewden C, Saag M, Mugavero M, Reiss P, et al. Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohorts. Clin Infect Dis 2010; 50:1387-1396.
23. Kesselring A, Gras L, Smit C, van-Twillert G, Verbon A, de-Wolf F, et al. Immunodeficiency as a risk factor for non-AIDSdefining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011; 52:1458-1465.
24. Petoumenos K, van-Leuwen MT, Vajdic CM, Woolley I, Chuah J, Templeton DJ, et al. Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Med 2013; 14:77-84.
25. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De-Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.
26. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JEL, Shah T, Sofat R, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet 2012; 379:1214-1224.
27. (CCGC) CRPCHDGC. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ 2011; 342:8.
28. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503.
29. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
30. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization; 2013. http://www.who.int/hiv/pub/guidelines/arv2013/en/[Accessed 11 September 2013].
31. British HIV Association. BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012. http://www.bhiva.org/documents/Guidelines/Treatment/2012/120430TreatmentGuidelines.pdf [Accessed 17December2013].
32. Mocroft A, Lundgren AC, Sabin ML, Monforte A, Brockmeyer N, Casabona J. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological research europe Study (COHERE). PLoS Med 2013; 10:e1001510.
33. Kaulich Bartz J, Dam W, May MT, Ledergerber B, Widmer U, Phillips AN, et al. Insurability of HIV positive people treated with combination antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS 2013; 27:15.
34. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med 2000; 50:1599-1605.
35. Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, Pedersen C, et al. Mortality attributable to smoking among HIV-1-infected individuals: A nationwide, population-based cohort study. Clin Infect Dis 2013; 56:727-734.
36. Justice A, Sullivan L, Fiellin D. HIV/AIDS, comorbidity, and alcohol. Alcohol Res Health 2010; 33:258-266.
37. Kirby T, Thornber-Dunwell M. High-risk drug practices tighten grip on London gay scene. Lancet 2013; 381:101-102.
38. Kirby T, Thornber-Dunwell M. New HIV diagnoses in London's gay men continue to soar. Lancet 2013; 382:295.
39. Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, et al. Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. PLoS One 2012; 7:e49314.
40. Konopnicki D, Mocroft A, de-Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.
41. Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, et al. The prevalence of hepatitis C virus (HCV) infection in HIVpositive individuals in the UK - Trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat 2010; 17:569-577.